1. 1407PDerived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (23rd October 2018) Authors: Mezquita, L; Arbour, K; Auclin, E; Saravia, D; Rizvi, H; Hendriks, L; Planchard, D; Park, W; Nadal, E; Ruffinelli Rodriguez, J C; Ponce, S; Audigier-Valette, C; Marilniello, A P; Zalcman, G; Majem, M; Schiavone, G; Dingemans, A-M C; Lopes, G; Hellmann, M D; Besse, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1763PMalnutrition in cancer patients: Is late diagnosis a missed opportunity to improve care?. (23rd October 2018) Authors: Tlemsani, C; Zalcman, G; Bernard, R; Zerouali, A; Goldwasser, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CPC-099 Patients on Vitamin K Antagonists (the Benefit of Pharmacy Students Educating VKA Patients in an University Hospital). (12th March 2013) Authors: Breuil, C; Baudon-Lecame, M; Hecquard, C; Le Hello, C; Lequerrec, A; Zalcman, G; Bergot, E Journal: European journal of hospital pharmacy Issue: Volume 20(2013)Supplement 1 Page Start: A200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. (4th October 2019) Authors: Moro-Sibilot, D; Cozic, N; Pérol, M; Mazières, J; Otto, J; Souquet, P J; Bahleda, R; Wislez, M; Zalcman, G; Guibert, S D; Barlési, F; Mennecier, B; Monnet, I; Sabatier, R; Bota, S; Dubos, C; Verriele, V; Haddad, V; Ferretti, G; Cortot, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. (24th May 2019) Authors: Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. (30th March 2018) Authors: Derosa, L; Hellmann, M D; Spaziano, M; Halpenny, D; Fidelle, M; Rizvi, H; Long, N; Plodkowski, A J; Arbour, K C; Chaft, J E; Rouche, J A; Zitvogel, L; Zalcman, G; Albiges, L; Escudier, B; Routy, B Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prophylactic radiotherapy to prevent procedure-tract metastases. Issue 10 (October 2016) Authors: Zalcman, G; Brosseau, S; Scherpereel, A Journal: Lancet oncology Issue: Volume 17:Issue 10(2016:Oct.) Page Start: e417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗